Advanced Filters
noise

Systemic Lupus Erythematosus Clinical Trials

A listing of Systemic Lupus Erythematosus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 289 clinical trials
C Cai Shaozhe, MD

Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus (SLE) is a highly specific autoimmune disease that involves multiple systems due to abnormal immune activation. It is a classical diffuse connective tissue disease with autoimmune inflammation as its prominent manifestation. B cells are the core of systemic lupus erythematosus (SLE) pathogenesis. B Lymphocyte Stimulator (BLyS, also …

18 - 70 years of age All Phase N/A
N Noemie GENSOUS, MD

Systemic Lupus Erythematosus and Accelerated Aging

The study aims at evaluating the phenomena of immune system aging in patients with Systemic lupus erythematosus.

18 - 60 years of age All Phase N/A
N Nicolas Guillaume, Pr

HLA Antibodies in Systemic Lupus Erythematosus

Patients suffering from autoimmune diseases show false-positive results when anti-HLA antibodies are identified. This false positivity makes it difficult to obtain an organ transplant based on immunological compatibility (absence of anti-HLA antibodies directed against graft antigens). The objectives of this project are to study the prevalence of these false positivities …

18 years of age All Phase N/A
S SAMI XI, dr

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.

18 - 90 years of age All Phase 1/2
X Xiaojing Zhang, MD

Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus

The goal of this clinical trial is to learn if blinatumomab works to treat refractory or active systemic lupus erythematosus (SLE) in children and adults. It will also learn about the safety of blinatumomab. The main questions it aims to answer are: Does blinatumomab improve symptoms and disease activity in …

5 years of age All Phase 1
W Wafia Nadia WN Nibouche-Hattab, MD

Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus

This is an observational, monocentric, retrospective cohort study. Its primary objective is to examine maternal and foetal outcomes in pregnancies that occurred before the diagnosis of systemic lupus erythematosus (SLE) in a group of female participants who were subsequently diagnosed with the condition.

18 - 55 years of age Female Phase N/A
Y Yann Mopsus, MSc

Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique

Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population of the French West Indies by chlordecone. Epidemiological studies conducted in the French West Indies …

18 years of age All Phase N/A
S Shorouk Mohamed abdelmageed, master degree

Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus

This study aims to investigate the association between the systemic immune-inflammation index and disease activity, as well as lupus nephritis in patients with systemic lupus erythematosus

16 years of age All Phase N/A

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus

18 - 75 years of age All Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with moderately to severely active systemic lupus erythematosus (SLE), including lupus nephritis and extra renal lupus. Approximately 30 participants will receive two …

18 - 65 years of age All Phase 1

Simplify language using AI